Study characteristics for pharmacotherapy studies.
| Study | Study Type | N (dropouts) | Duration | Placebo Comparator | Overall RoB |
|---|---|---|---|---|---|
| Sundy4 2011, USA, Canada, Mexico | 2 × RCT | 225 (19) | 25 wks | Allopurinol | Unclear |
| Becker5 2009, USA, Canada | Open-label extension | 1086 (168) | 3 yrs | Allopurinol (max 300 mg/day) or benzbromarone (max 200 mg/day) alone | High |
| Perez-Ruiz6 2002, Spain | Cohort (prospective observational) | 70 (7) | 6 mo | Allopurinol (200 mg/day) + benzbromarone (50 mg/day) | High |
RCT: randomized controlled trial; RoB: Risk of Bias assessment.